West Pharmaceutical Services
WST
390.30
-6.39
-1.61%
West Pharmaceutical Services
US · WST
#752 by market cap
Listed 1970
390.30
-6.39
-1.61%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Visteon Is Maintained at Buy by UBSDow Jones · 2026/10/24
-
Company notice
Visteon | 8-K: Visteon Announces Third Quarter 2026 Financial ResultsSEC · 2026/10/22
-
Rating change
Citi Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Maintains Target Price $494Market Newswire · 2026/10/30
-
Press Release: Visteon Declares Quarterly Dividend of $0.375 Per ShareDow Jones · 2026/11/17
-
Rating change
A Quick Look at Today's Ratings for Visteon(VC.US), With a Forecast Between $95 to $135Market Newswire · 2026/10/24
-
RBC Capital Maintains Visteon(VC.US) With Buy Rating, Raises Target Price to $102Market Newswire · 2026/11/13
-
Visteon To Go Ex-Dividend On December 1st, 2026 With 0.375 USD Dividend Per ShareMarket Newswire · 2026/11/18
-
Rating change
Barclays Maintains Overweight on Visteon, Lowers Price Target to $105Benzinga · 2026/10/29
-
Company notice
10-Q: Visteon | 10-Q: Q2 2026 Earnings ReportSEC · 2026/7/23
-
Rating change
Citi Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $494Market Newswire · 2026/10/30
-
Company notice
Visteon | 8-K: Current reportSEC · 2026/10/28
-
Rating change
UBS Maintains Buy on Visteon, Lowers Price Target to $96Benzinga · 2026/10/24
-
A Quick Look at Today's Ratings for West Pharmaceutical Services(WST.US), With a Forecast Between $480 to $500Market Newswire · 2026/10/31
-
J.P. Morgan Maintains Visteon(VC.US) With Buy Rating, Maintains Target Price $135Market Newswire · 2026/11/10
-
Company notice
Visteon | SCHEDULE 13G/A: OthersSEC · 2026/10/7
-
Company notice
Visteon | 10-Q: Q3 2026 Earnings ReportSEC · 2026/10/22
-
Rating change
Barclays Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $500Market Newswire · 2026/10/30
-
Rating change
Visteon Is Maintained at Overweight by JP MorganDow Jones · 2026/10/24
-
Rating change
Visteon Is Maintained at Overweight by BarclaysDow Jones · 2026/10/29
-
Rating change
Barclays Maintains Visteon(VC.US) With Buy Rating, Cuts Target Price to $105Market Newswire · 2026/10/28
-
Rating change
RBC Capital Maintains Outperform on Visteon, Lowers Price Target to $100Benzinga · 2026/10/23
-
Rating change
Visteon Is Maintained at Outperform by RBC CapitalDow Jones · 2026/10/23
-
Rating change
Visteon Price Target Cut to $135.00/Share From $145.00 by JP MorganDow Jones · 2026/10/24
-
Rating change
JP Morgan Maintains Overweight on Visteon, Lowers Price Target to $135Benzinga · 2026/10/24
-
Rating change
Barclays Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $440Market Newswire · 2026/10/7
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
West Pharmaceutical Services discussion 0 comments